JP2022512234A5 - - Google Patents

Info

Publication number
JP2022512234A5
JP2022512234A5 JP2021533356A JP2021533356A JP2022512234A5 JP 2022512234 A5 JP2022512234 A5 JP 2022512234A5 JP 2021533356 A JP2021533356 A JP 2021533356A JP 2021533356 A JP2021533356 A JP 2021533356A JP 2022512234 A5 JP2022512234 A5 JP 2022512234A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
fusion protein
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512234A (ja
JP7444886B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065741 external-priority patent/WO2020123662A2/en
Publication of JP2022512234A publication Critical patent/JP2022512234A/ja
Publication of JP2022512234A5 publication Critical patent/JP2022512234A5/ja
Priority to JP2024025175A priority Critical patent/JP7811315B2/ja
Application granted granted Critical
Publication of JP7444886B2 publication Critical patent/JP7444886B2/ja
Priority to JP2025279839A priority patent/JP2026053563A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533356A 2018-12-11 2019-12-11 補体関連疾患のための融合タンパク質構築物 Active JP7444886B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024025175A JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物
JP2025279839A JP2026053563A (ja) 2018-12-11 2025-12-24 補体関連疾患のための融合タンパク質構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11
US62/778,014 2018-12-11
PCT/US2019/065741 WO2020123662A2 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024025175A Division JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物

Publications (3)

Publication Number Publication Date
JP2022512234A JP2022512234A (ja) 2022-02-02
JP2022512234A5 true JP2022512234A5 (https=) 2023-07-31
JP7444886B2 JP7444886B2 (ja) 2024-03-06

Family

ID=71076704

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021533356A Active JP7444886B2 (ja) 2018-12-11 2019-12-11 補体関連疾患のための融合タンパク質構築物
JP2024025175A Active JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物
JP2025279839A Pending JP2026053563A (ja) 2018-12-11 2025-12-24 補体関連疾患のための融合タンパク質構築物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024025175A Active JP7811315B2 (ja) 2018-12-11 2024-02-22 補体関連疾患のための融合タンパク質構築物
JP2025279839A Pending JP2026053563A (ja) 2018-12-11 2025-12-24 補体関連疾患のための融合タンパク質構築物

Country Status (13)

Country Link
US (1) US20240301043A1 (https=)
EP (1) EP3893916A4 (https=)
JP (3) JP7444886B2 (https=)
KR (2) KR20250021629A (https=)
CN (1) CN113660944A (https=)
AU (2) AU2019398214C1 (https=)
IL (1) IL283841A (https=)
MA (1) MA54468A (https=)
MX (1) MX2021006930A (https=)
MY (1) MY209796A (https=)
PH (1) PH12021551398A1 (https=)
SG (1) SG11202106073QA (https=)
WO (1) WO2020123662A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075783A2 (en) * 2016-10-20 2018-04-26 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
KR20220019806A (ko) * 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
CN114778418B (zh) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
KR20250057830A (ko) * 2022-08-30 2025-04-29 롱바이오 파마 (수조우) 컴퍼니 리미티드 항-인간 보체 c5 항체 및 이의 융합 단백질
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119431565B (zh) * 2025-01-10 2025-04-08 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP1284752A4 (en) * 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
AU2002361106B2 (en) * 2001-12-28 2007-06-07 Kyowa Hakko Kirin Co., Ltd. Remedies for arthritis
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG186397A1 (en) * 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
US8940490B2 (en) 2010-11-29 2015-01-27 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
HK1218300A1 (zh) * 2013-01-23 2017-02-10 Musc Foundation For Research Development 基於天然抗體的靶向結構體及其應用
CA2930665A1 (en) * 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US10035848B2 (en) * 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
MA39819A (fr) * 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
WO2015187992A2 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
CN120988137A (zh) * 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体

Similar Documents

Publication Publication Date Title
JP2022512234A5 (https=)
JP7257971B6 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
IL272747B1 (en) Bispecific antibodies 1 + 2
NZ717476A (en) Anti-garp protein and uses thereof
JP2024059791A5 (https=)
JP2020524661A5 (https=)
TW201527322A (zh) 骨關節炎及疼痛之治療
JP2024059791A (ja) 補体関連疾患のための融合タンパク質構築物
JP2021520832A5 (https=)
TW201333033A (zh) 雙可變域免疫球蛋白及其用途
PE20230408A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
JP2021533159A5 (https=)
HRP20241013T1 (hr) Protutijela za kelatirane radionuklide
JP2018093875A5 (https=)
JP2019507580A5 (https=)
JP2022513043A5 (https=)
JP2019505166A5 (https=)
JP2026004299A5 (https=)
JP2024119984A5 (https=)
AR114436A1 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
RU2008140947A (ru) Антитела к egfl7 и способы их применения
JP2025160405A (ja) 特異的結合分子
JP2022501065A5 (https=)
JP2021518132A5 (https=)
JP2023506162A (ja) 抗bcma/抗4-1bb二重特異性抗体及びその用途